

# Jeffrey L Cummings

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1889933/jeffrey-l-cummings-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

350  
papers

47,336  
citations

89  
h-index

216  
g-index

389  
ext. papers

57,693  
ext. citations

7  
avg, IF

7.74  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 350 | The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. <i>Journal of the American Geriatrics Society</i> , <b>2005</b> , 53, 695-9                                     | 5.6  | 11162     |
| 349 | Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , <b>2007</b> , 6, 734-46  | 24.1 | 3067      |
| 348 | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , <b>2014</b> , 13, 614-29   | 24.1 | 1985      |
| 347 | Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 1689-707; quiz 1837   | 7    | 1968      |
| 346 | Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. <i>Nature Genetics</i> , <b>2011</b> , 43, 436-41   | 36.3 | 1367      |
| 345 | Alzheimer's disease. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 56-67   | 59.2 | 1096      |
| 344 | Alzheimer's disease drug-development pipeline: few candidates, frequent failures. <i>Alzheimer's Research and Therapy</i> , <b>2014</b> , 6, 37  | 9    | 1023      |
| 343 | Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2000</b> , 12, 233-9                                       | 2.7  | 944       |
| 342 | The spectrum of behavioral changes in Alzheimer's disease. <i>Neurology</i> , <b>1996</b> , 46, 130-5  | 6.5  | 863       |
| 341 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 292-323   | 1.2  | 832       |
| 340 | Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15056  | 51.1 | 755       |
| 339 | The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. <i>Alzheimer Disease and Associated Disorders</i> , <b>2006</b> , 20, 210-6                  | 2.5  | 568       |
| 338 | The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. <i>Alzheimer Disease and Associated Disorders</i> , <b>2009</b> , 23, 91-101                                       | 2.5  | 525       |
| 337 | Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , <b>2014</b> , 383, 533-40  | 40   | 519       |
| 336 | Apathy is not depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>1998</b> , 10, 314-9   | 2.7  | 437       |
| 335 | Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. <i>Archives of Neurology</i> , <b>2006</b> , 63, 693-9   |      | 391       |
| 334 | Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. <i>Journal of the American Geriatrics Society</i> , <b>1998</b> , 46, 210-5 | 5.6  | 383       |

|     |  |      |     |
|-----|--|------|-----|
| 333 | Alzheimer's disease drug development pipeline: 2019. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 272-293   | 6    | 378 |
| 332 | Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1691-1703   | 59.2 | 370 |
| 331 | Alzheimer's disease drug development pipeline: 2018. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 195-214   | 6    | 359 |
| 330 | PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 20, 509-16   | 4.3  | 306 |
| 329 | The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement. <i>American Journal of Geriatric Psychiatry</i> , <b>2000</b> , 8, 75-83  | 6.5  | 294 |
| 328 | Alzheimer disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 2335-8   | 27.4 | 287 |
| 327 | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting. <i>Journal of the American Geriatrics Society</i> , <b>2001</b> , 49, 1590-1599 | 5.6  | 269 |
| 326 | Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1408-1420  | 59.2 | 268 |
| 325 | Management of agitation and aggression associated with Alzheimer disease. <i>Nature Reviews Neurology</i> , <b>2009</b> , 5, 245-55  | 15   | 260 |
| 324 | Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. <i>Lancet Neurology</i> , <b>2007</b> , 6, 501-12  | 24.1 | 260 |
| 323 | Alzheimer's disease drug development pipeline: 2017. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 367-384   | 6    | 256 |
| 322 | Management of behavioral problems in Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2010</b> , 22, 346-72   | 3.4  | 251 |
| 321 | Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2008</b> , 25, 115-26  | 2.6  | 250 |
| 320 | Alzheimer's disease. <i>Lancet, The</i> , <b>2021</b> , 397, 1577-1590   | 40   | 245 |
| 319 | Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 821-853   | 14.3 | 236 |
| 318 | Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 39   | 9    | 234 |
| 317 | Provisional Diagnostic Criteria for Depression of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , <b>2002</b> , 10, 125-128   | 6.5  | 234 |
| 316 | Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. <i>Annals of Neurology</i> , <b>2001</b> , 49, 355-361  | 9.4  | 222 |

|     |   |      |     |
|-----|---|------|-----|
| 315 | A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. <i>International Journal of Geriatric Psychiatry</i> , <b>2007</b> , 22, 456-67        | 3.9  | 219 |
| 314 | Disease-modifying therapies for Alzheimer disease: challenges to early intervention. <i>Neurology</i> , <b>2007</b> , 69, 1622-34   | 6.5  | 217 |
| 313 | Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. <i>Annals of Neurology</i> , <b>2010</b> , 68, 693-702  | 9.4  | 202 |
| 312 | On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 60   | 9    | 197 |
| 311 | Serotonin 1A receptors in the living brain of Alzheimer's disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 702-7   | 11.5 | 196 |
| 310 | Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. <i>Brain</i> , <b>2007</b> , 130, 1767-76  | 11.2 | 195 |
| 309 | The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. <i>Archives of Neurology</i> , <b>1999</b> , 56, 1388-93   |      | 193 |
| 308 | Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. <i>Alzheimer Disease and Associated Disorders</i> , <b>2004</b> , 18, 17-21  | 2.5  | 188 |
| 307 | The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 56, 929-938   | 4.3  | 182 |
| 306 | Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. <i>International Psychogeriatrics</i> , <b>2015</b> , 27, 7-17                                      | 3.4  | 181 |
| 305 | Functional correlates of musical and visual ability in frontotemporal dementia. <i>British Journal of Psychiatry</i> , <b>2000</b> , 176, 458-63  | 5.4  | 180 |
| 304 | Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. <i>Neurology</i> , <b>2006</b> , 67, 57-63   | 6.5  | 174 |
| 303 | Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. <i>Neurobiology of Aging</i> , <b>2000</b> , 21, 845-61   | 5.6  | 166 |
| 302 | Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. <i>Journal of Clinical Psychiatry</i> , <b>2008</b> , 69, 889-98 | 4.6  | 166 |
| 301 | Prevalence and impact of medical comorbidity in Alzheimer's disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2002</b> , 57, M173-7  | 6.4  | 165 |
| 300 | Neuropsychiatric Symptoms and Quality of Life in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , <b>2005</b> , 13, 469-474   | 6.5  | 164 |
| 299 | Behavioural changes and psychological symptoms in dementia disorders. <i>Lancet Neurology</i> , <b>2005</b> , 4, 735-42   | 24.1 | 164 |
| 298 | Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 67, 779-794   | 4.3  | 163 |

|     |  |      |     |
|-----|--|------|-----|
| 297 | Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. <i>Neurology</i> , <b>2007</b> , 68, 1356-63   | 6.5  | 162 |
| 296 | Alzheimer's disease drug development pipeline: 2020. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2020</b> , 6, e12050  | 6    | 161 |
| 295 | Positron emission tomography metabolic correlates of apathy in Alzheimer disease. <i>Archives of Neurology</i> , <b>2007</b> , 64, 1015-20   |      | 158 |
| 294 | Defining and diagnosing involuntary emotional expression disorder. <i>CNS Spectrums</i> , <b>2006</b> , 11, 1-7  | 1.8  | 152 |
| 293 | Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. <i>Clinical and Translational Science</i> , <b>2018</b> , 11, 147-152  | 4.9  | 149 |
| 292 | Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. <i>Archives of General Psychiatry</i> , <b>2011</b> , 68, 853-61   |      | 146 |
| 291 | The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. <i>Brain</i> , <b>2011</b> , 134, 3146-66   | 11.2 | 144 |
| 290 | Executive dysfunction in Alzheimer disease. <i>Archives of Neurology</i> , <b>2004</b> , 61, 556-60  |      | 144 |
| 289 | Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 341-9   | 11.9 | 140 |
| 288 | Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2007</b> , 24, 253-9                       | 2.6  | 130 |
| 287 | Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>1996</b> , 9, 1-6  | 3.8  | 129 |
| 286 | ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 90, e1889-e1897   | 6.5  | 123 |
| 285 | Structural correlates of apathy in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2007</b> , 24, 91-7   | 2.6  | 120 |
| 284 | Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 532-8                                  | 11.9 | 120 |
| 283 | Behavioral complications of drug treatment of Parkinson's disease. <i>Journal of the American Geriatrics Society</i> , <b>1991</b> , 39, 708-16  | 5.6  | 119 |
| 282 | Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 1242-54 | 27.4 | 118 |
| 281 | 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 1284-303   | 5.6  | 114 |
| 280 | The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. <i>Journal of Sleep Research</i> , <b>2003</b> , 12, 331-7                                      | 5.8  | 113 |

|     |  |      |     |
|-----|--|------|-----|
| 279 | Comparison of neuropsychological functioning in Alzheimer's disease and frontotemporal dementia. <i>Journal of the International Neuropsychological Society</i> , <b>1996</b> , 2, 505-10  | 3.1  | 112 |
| 278 | Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. <i>Archives of Neurology</i> , <b>2000</b> , 57, 861-6  |      | 108 |
| 277 | Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. <i>Archives of Neurology</i> , <b>2004</b> , 61, 1249-53   |      | 107 |
| 276 | Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. <i>American Journal of Geriatric Psychiatry</i> , <b>2006</b> , 14, 605-12  | 6.5  | 106 |
| 275 | Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). <i>International Journal of Geriatric Psychiatry</i> , <b>2001</b> , 16, 789-93  | 3.9  | 105 |
| 274 | Apathy and executive function in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , <b>2002</b> , 8, 373-81   | 3.1  | 105 |
| 273 | Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 4   | 9    | 104 |
| 272 | Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. <i>Current Alzheimer Research</i> , <b>2015</b> , 12, 712-22  | 3    | 104 |
| 271 | Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose F 18 positron emission tomographic study. <i>Archives of Neurology</i> , <b>2005</b> , 62, 721-8  |      | 104 |
| 270 | Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2001</b> , 13, 121-8  | 3.4  | 100 |
| 269 | Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. <i>Lancet Neurology</i> , <b>2018</b> , 17, 213-222 | 24.1 | 99  |
| 268 | Neuropsychiatric symptoms and quality of life in Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , <b>2005</b> , 13, 469-74   | 6.5  | 97  |
| 267 | Neuropathologic correlates of apathy in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2006</b> , 21, 144-7   | 2.6  | 95  |
| 266 | The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 76   | 9    | 93  |
| 265 | Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 130-142     | 27.4 | 92  |
| 264 | A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A $\beta$ protofibril antibody. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 80                               | 9    | 92  |
| 263 | Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. <i>Archives of Neurology</i> , <b>2009</b> , 66, 888-93   |      | 89  |
| 262 | A videotape-based training method for improving the detection of depression in residents of long-term care facilities. <i>Gerontologist</i> , <b>2002</b> , 42, 114-21   | 5    | 89  |

|     |   |      |    |
|-----|---|------|----|
| 261 | Behavioral disorders in Alzheimer disease: a transcultural perspective. <i>Archives of Neurology</i> , <b>1998</b> , 55, 539-44   |      | 88 |
| 260 | Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2002</b> , 13, 67-73  | 2.6  | 86 |
| 259 | Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , <b>2021</b> , 20, 484-496  | 24.1 | 86 |
| 258 | ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 993-9   | 5.5  | 82 |
| 257 | The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. <i>European Journal of Haematology</i> , <b>1995</b> , 54, 245-53   | 3.8  | 80 |
| 256 | Toward a molecular neuropsychiatry of neurodegenerative diseases. <i>Annals of Neurology</i> , <b>2003</b> , 54, 147-54   |      | 80 |
| 255 | 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. <i>Human Brain Mapping</i> , <b>2010</b> , 31, 786-97  | 5.9  | 79 |
| 254 | Alzheimer's drug-development pipeline: 2016. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2016</b> , 2, 222-232  | 6    | 76 |
| 253 | Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale. <i>Journal of the American Geriatrics Society</i> , <b>1992</b> , 40, 549-55   | 5.6  | 75 |
| 252 | Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 64, S3-S22   | 4.3  | 74 |
| 251 | Psychological dysfunction accompanying subcortical dementias. <i>Annual Review of Medicine</i> , <b>1988</b> , 39, 53-61  | 17.4 | 72 |
| 250 | Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. <i>NeuroImage</i> , <b>2010</b> , 51, 488-99  | 7.9  | 71 |
| 249 | Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. <i>CNS Neuroscience and Therapeutics</i> , <b>2016</b> , 22, 159-66  | 6.8  | 69 |
| 248 | Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm <sup>2</sup> ) in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2012</b> , 33, 341-53 | 2.6  | 65 |
| 247 | The Amyloid- $\beta$ Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , <b>2021</b> ,  | 15.1 | 63 |
| 246 | Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , <b>2018</b> , 130, 331-365  | 10.2 | 60 |
| 245 | A review: treatment of Alzheimer's disease discovered in repurposed agents. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2013</b> , 35, 1-22  | 2.6  | 59 |
| 244 | The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 172-178   | 1.2  | 59 |

|     |   |      |    |
|-----|---|------|----|
| 243 | Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 169-83           | 5.6  | 58 |
| 242 | Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 98                          | 9    | 57 |
| 241 | Guidelines for managing Alzheimer's disease: part I. Assessment. <i>American Family Physician</i> , <b>2002</b> , 65, 2263-72   | 1.3  | 57 |
| 240 | Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 43, 949-55              | 4.3  | 55 |
| 239 | International Work Group criteria for the diagnosis of Alzheimer disease. <i>Medical Clinics of North America</i> , <b>2013</b> , 97, 363-8                                       | 7    | 55 |
| 238 | Treatment of Alzheimer's disease: current and future therapeutic approaches. <i>Reviews in Neurological Diseases</i> , <b>2004</b> , 1, 60-9                                      |      | 55 |
| 237 | Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , <b>2015</b> , 138, 1036-45                                | 11.2 | 54 |
| 236 | What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?. <i>Biological Psychiatry</i> , <b>2010</b> , 68, 876-8                | 7.9  | 54 |
| 235 | Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2004</b> , 17, 32-5  | 3.8  | 54 |
| 234 | Guidelines for managing Alzheimer's disease: Part II. Treatment. <i>American Family Physician</i> , <b>2002</b> , 65, 2525-34   | 1.3  | 54 |
| 233 | Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. <i>Archives of Neurology</i> , <b>2012</b> , 69, 901-5                                  |      | 53 |
| 232 | ADCS Prevention Instrument Project: overview and initial results. <i>Alzheimer Disease and Associated Disorders</i> , <b>2006</b> , 20, S109-23                                   | 2.5  | 53 |
| 231 | Alzheimer's disease drug development pipeline: 2021. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12179                 | 6    | 53 |
| 230 | A practical algorithm for managing Alzheimer's disease: what, when, and why?. <i>Annals of Clinical and Translational Neurology</i> , <b>2015</b> , 2, 307-23                     | 5.3  | 52 |
| 229 | Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2014</b> , 37, 315-26 | 2.6  | 52 |
| 228 | Quantitative EEG in frontotemporal dementia. <i>Clinical EEG (electroencephalography)</i> , <b>1996</b> , 27, 61-8  |      | 50 |
| 227 | Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 295-9       | 3.6  | 49 |
| 226 | Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2012</b> , 2, a006395                 | 5.4  | 48 |



|     |   |     |    |
|-----|---|-----|----|
| 225 | Discovering new treatments for Alzheimer's disease by repurposing approved medications. <i>Current Topics in Medicinal Chemistry</i> , <b>2013</b> , 13, 2306-27  | 3   | 48 |
| 224 | Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 176-88   | 1.2 | 45 |
| 223 | High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. <i>CNS Neuroscience and Therapeutics</i> , <b>2013</b> , 19, 294-301  | 6.8 | 44 |
| 222 | Integrating ADNI results into Alzheimer's disease drug development programs. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 1481-92   | 5.6 | 44 |
| 221 | Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , <b>2020</b> , 16, 661-673   | 15  | 44 |
| 220 | Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. <i>BMC Neurology</i> , <b>2011</b> , 11, 21  | 3.1 | 43 |
| 219 | Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. <i>Molecular Genetics and Metabolism</i> , <b>2003</b> , 80, 350-5 | 3.7 | 43 |
| 218 | Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2000</b> , 12, 209-18   | 2.7 | 43 |
| 217 | Utilization of Alzheimer's disease community resources by Asian-Americans in California. <i>International Journal of Geriatric Psychiatry</i> , <b>2000</b> , 15, 838-47  | 3.9 | 43 |
| 216 | The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 189-98  | 1.2 | 42 |
| 215 | Defining and labeling disease-modifying treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2009</b> , 5, 406-18   | 1.2 | 41 |
| 214 | Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2001</b> , 14, 101-8   | 3.8 | 41 |
| 213 | Gender-related cognitive deficits in Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>1999</b> , 11, 117-22  | 3.4 | 41 |
| 212 | Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 62-72   | 5.6 | 40 |
| 211 | The Role of Biomarkers in Alzheimer's Disease Drug Development. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1118, 29-61  | 3.6 | 40 |
| 210 | Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. <i>Journal of Prevention of Alzheimer's Disease</i> , <b>2019</b> , 6, 157-163  | 3.8 | 39 |
| 209 | The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 1913-20   | 5.6 | 39 |
| 208 | Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 47, 205-14  | 4.3 | 39 |

|     |   |      |    |
|-----|---|------|----|
| 207 | The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , <b>2014</b> , 4, 509-16                      | 2.5  | 39 |
| 206 | Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , <b>2011</b> , 26, 150-7  | 3.9  | 39 |
| 205 | Neuropathologic correlates of activities of daily living in Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , <b>2006</b> , 20, 56-9   | 2.5  | 39 |
| 204 | Disease modification and Neuroprotection in neurodegenerative disorders. <i>Translational Neurodegeneration</i> , <b>2017</b> , 6, 25   | 10.3 | 38 |
| 203 | Clinical trials in predementia stages of Alzheimer disease. <i>Medical Clinics of North America</i> , <b>2013</b> , 97, 439-57  | 7    | 37 |
| 202 | Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2013</b> , 25, 707-19   | 3.4  | 37 |
| 201 | Incidence of dementia and subtypes: A cohort study in four regions in China. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 262-71   | 1.2  | 36 |
| 200 | Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. <i>Movement Disorders</i> , <b>2001</b> , 16, 1098-104   | 7    | 36 |
| 199 | New approaches to symptomatic treatments for Alzheimer's disease. <i>Molecular Neurodegeneration</i> , <b>2021</b> , 16, 2  | 19   | 35 |
| 198 | Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2015</b> , 28, 159-73   | 3.8  | 34 |
| 197 | Overcoming obstacles to repurposing for neurodegenerative disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2014</b> , 1, 512-8   | 5.3  | 34 |
| 196 | Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2012</b> , 33, 1-5  | 2.6  | 34 |
| 195 | Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. <i>Nature Reviews Drug Discovery</i> , <b>2006</b> , 5, 64-74  | 64.1 | 34 |
| 194 | Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. <i>American Journal of Geriatric Psychiatry</i> , <b>2013</b> , 21, 607-22 | 6.5  | 33 |
| 193 | Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2010</b> , 22, 973-83   | 3.4  | 33 |
| 192 | De Clombault's syndrome in organic affective disorder. Two cases. <i>British Journal of Psychiatry</i> , <b>1987</b> , 151, 404-7   | 5.4  | 33 |
| 191 | The price of progress: Funding and financing Alzheimer's disease drug development. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 330-343  | 6    | 33 |
| 190 | Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. <i>American Journal of Geriatric Psychiatry</i> , <b>2003</b> , 11, 131-45   | 6.5  | 33 |

|     |  |      |    |
|-----|--|------|----|
| 189 | Dementia with lewy bodies: molecular pathogenesis and implications for classification. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2004</b> , 17, 112-9  | 3.8  | 31 |
| 188 | Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. <i>American Journal of Geriatric Psychiatry</i> , <b>2020</b> , 28, 383-400   | 6.5  | 31 |
| 187 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. <i>Journal of Prevention of Alzheimer's Disease</i> , <b>2018</b> , 5, 253-258   | 3.8  | 31 |
| 186 | Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 173-181  | 6    | 30 |
| 185 | Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2005</b> , 17, 81-90  | 3.4  | 30 |
| 184 | National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. <i>Neurology</i> , <b>2021</b> , 96, 848-863  | 6.5  | 30 |
| 183 | Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 72   | 9    | 29 |
| 182 | Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study. <i>Experimental Gerontology</i> , <b>2018</b> , 111, 118-121 | 4.5  | 28 |
| 181 | A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 62   | 9    | 28 |
| 180 | Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , <b>2019</b> , 217, 72-83               | 4.9  | 27 |
| 179 | Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 1131-1139  | 4.3  | 27 |
| 178 | Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. <i>Journal of Prevention of Alzheimer's Disease</i> , <b>2017</b> , 4, 149-156   | 3.8  | 27 |
| 177 | Altered Behavior Associated with Damage to the Ventromedial Hypothalamus: A Distinctive Syndrome. <i>Behavioural Neurology</i> , <b>1988</b> , 1, 49-58  | 3    | 26 |
| 176 | Aducanumab: Appropriate Use Recommendations. <i>Journal of Prevention of Alzheimer's Disease</i> , <b>2021</b> , 8, 398-410  | 3.8  | 26 |
| 175 | Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , <b>2014</b> , 4, 335-43  | 2.5  | 25 |
| 174 | Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. <i>Medicinal Research Reviews</i> , <b>2020</b> , 40, 2386-2426   | 14.4 | 25 |
| 173 | Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 580-589   | 15   | 25 |
| 172 | Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. <i>BMC Geriatrics</i> , <b>2013</b> , 13, 56   | 4.1  | 23 |

|     |  |     |    |
|-----|--|-----|----|
| 171 | Globalization of Alzheimer's disease clinical trials. <i>Alzheimer's Research and Therapy</i> , <b>2011</b> , 3, 24  | 9   | 23 |
| 170 | The Neuropsychiatric Inventory: Development and Applications. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2020</b> , 33, 73-84   | 3.8 | 23 |
| 169 | Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 68  | 9   | 22 |
| 168 | Alzheimer's disease drug development: translational neuroscience strategies. <i>CNS Spectrums</i> , <b>2013</b> , 18, 128-38   | 1.8 | 22 |
| 167 | Advances in designs for Alzheimer's disease clinical trials. <i>American Journal of Neurodegenerative Disease</i> , <b>2012</b> , 1, 205-16  | 2.5 | 22 |
| 166 | Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. <i>Expert Review of Clinical Pharmacology</i> , <b>2014</b> , 7, 161-5  | 3.8 | 21 |
| 165 | Speech and language alterations in dementia syndromes: Characteristics and treatment. <i>Aphasiology</i> , <b>1990</b> , 4, 339-352  | 1.6 | 21 |
| 164 | Alzheimer's disease progression by geographical region in a clinical trial setting. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 43  | 9   | 20 |
| 163 | Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. <i>Current Psychiatry Reports</i> , <b>2019</b> , 21, 79   | 9.1 | 20 |
| 162 | Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , <b>2012</b> , 27, 421-32 | 2.5 | 20 |
| 161 | Reviewing the role of donepezil in the treatment of Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2012</b> , 9, 773-81   | 3   | 20 |
| 160 | Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 1483-1492  | 1.2 | 20 |
| 159 | Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 66, 1223-1234   | 4.3 | 20 |
| 158 | Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 186  | 4.1 | 19 |
| 157 | Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia. <i>Journal of the American Geriatrics Society</i> , <b>2015</b> , 63, 1448-52                     | 5.6 | 18 |
| 156 | Optimizing phase II of drug development for disease-modifying compounds. <i>Alzheimer's and Dementia</i> , <b>2008</b> , 4, S15-20   | 1.2 | 18 |
| 155 | Neuropsychiatric aspects of dementia with Lewy bodies. <i>Current Psychiatry Reports</i> , <b>1999</b> , 1, 85-92  | 9.1 | 18 |
| 154 | Repurposed agents in the Alzheimer's disease drug development pipeline. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 98   | 9   | 18 |

|     |   |      |    |
|-----|---|------|----|
| 153 | Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 309-319  | 59.2 | 18 |
| 152 | Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 39   | 9    | 17 |
| 151 | Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. <i>Alzheimer Disease and Associated Disorders</i> , <b>2013</b> , 27, 174-81   | 2.5  | 17 |
| 150 | Controversies in Alzheimer's disease drug development. <i>International Review of Psychiatry</i> , <b>2008</b> , 20, 389-95   | 3.6  | 17 |
| 149 | The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , <b>2021</b> ,  | 13.5 | 17 |
| 148 | Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 73, 1143-1156                           | 4.3  | 17 |
| 147 | Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 69, 953-961  | 4.3  | 16 |
| 146 | Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. <i>Expert Review of Neurotherapeutics</i> , <b>2003</b> , 3, 99-106  | 4.3  | 16 |
| 145 | Neurobehavioural examination of frontal lobe functions. <i>Aphasiology</i> , <b>1995</b> , 9, 181-192   | 1.6  | 16 |
| 144 | BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. <i>Brain</i> , <b>2020</b> , 143, 3816-3826  | 11.2 | 16 |
| 143 | Statistical advances in clinical trials and clinical research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 366-371  | 6    | 15 |
| 142 | Alzheimer's disease biomarkers: correspondence between human studies and animal models. <i>Neurobiology of Disease</i> , <b>2013</b> , 56, 116-30   | 7.5  | 15 |
| 141 | Higher working memory predicts slower functional decline in autopsy-confirmed Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2014</b> , 38, 224-33   | 2.6  | 15 |
| 140 | A new measurement of activities of daily living for Thai elderly with dementia. <i>International Psychogeriatrics</i> , <b>2003</b> , 15, 135-48  | 3.4  | 15 |
| 139 | Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>1999</b> , 8, 463-71 | 5.9  | 15 |
| 138 | Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. <i>American Journal of Geriatric Psychiatry</i> , <b>2020</b> , 28, 1256-1269  | 6.5  | 15 |
| 137 | Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. <i>Reviews in Neurological Diseases</i> , <b>2007</b> , 4, 57-62   |      | 15 |
| 136 | Brain health INnovation Diplomacy: a model binding diverse disciplines to manage the promise and perils of technological innovation. <i>International Psychogeriatrics</i> , <b>2020</b> , 32, 955-979  | 3.4  | 14 |

|     |   |      |    |
|-----|---|------|----|
| 135 | Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 73   | 9    | 14 |
| 134 | AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 24   | 9    | 14 |
| 133 | Clinical drug development for dementia with Lewy bodies: past and present. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 951-965   | 5.9  | 13 |
| 132 | Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. <i>Translational Neurodegeneration</i> , <b>2014</b> , 3, 12  | 10.3 | 13 |
| 131 | Fluctuations in cognitive function in dementia with Lewy bodies. <i>Lancet Neurology</i> , <b>2004</b> , 3, 266   | 24.1 | 13 |
| 130 | Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease. <i>Nature Aging</i> , <b>2021</b> , 1, 1175-1188   |      | 13 |
| 129 | Alzheimer's disease biomarkers in animal models: closing the translational gap. <i>American Journal of Neurodegenerative Disease</i> , <b>2013</b> , 2, 108-20  | 2.5  | 13 |
| 128 | Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. <i>Neurology</i> , <b>2020</b> , 94, e774-e784   | 6.5  | 13 |
| 127 | Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. <i>Genome Research</i> , <b>2021</b> , 31, 1900-1912           | 9.7  | 13 |
| 126 | Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 102 | 9    | 13 |
| 125 | The "Alzheimer's type" profile of semantic clustering in amnesic mild cognitive impairment. <i>Journal of the International Neuropsychological Society</i> , <b>2014</b> , 20, 402-12   | 3.1  | 12 |
| 124 | Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , <b>2013</b> , 28, 583-91                   | 2.5  | 12 |
| 123 | Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 518-30    | 2.9  | 11 |
| 122 | Alzheimer's disease clinical trials: changing the paradigm. <i>Current Psychiatry Reports</i> , <b>2011</b> , 13, 437-42  | 9.1  | 11 |
| 121 | Clinical evaluation as a biomarker for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2005</b> , 8, 327-374.3  |      | 11 |
| 120 | ADCS Prevention Instrument Project: behavioral measures in primary prevention trials. <i>Alzheimer Disease and Associated Disorders</i> , <b>2006</b> , 20, S147-51   | 2.5  | 11 |
| 119 | Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors. <i>CNS Drugs</i> , <b>2000</b> , 13, 385-395  | 6.7  | 11 |
| 118 | Regression to the mean: implications for clinical trials of psychotropic agents in dementia. <i>Current Alzheimer Research</i> , <b>2004</b> , 1, 323-8   | 3    | 11 |

|     |  |     |    |
|-----|--|-----|----|
| 117 | The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. <i>American Journal of Geriatric Psychiatry</i> , <b>2021</b> , 29, 375-383  | 6.5 | 11 |
| 116 | Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 116   | 9   | 11 |
| 115 | Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 64, 79-89   | 4.3 | 11 |
| 114 | Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease. <i>Neurology</i> , <b>2021</b> , 97, 543-544   | 6.5 | 11 |
| 113 | A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 75, 547-557  | 4.3 | 10 |
| 112 | Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia. <i>International Psychogeriatrics</i> , <b>2013</b> , 25, 431-8  | 3.4 | 10 |
| 111 | Alzheimer's disease: from molecular biology to neuropsychiatry. <i>Seminars in Clinical Neuropsychiatry</i> , <b>2003</b> , 8, 31-6  |     | 10 |
| 110 | Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019". <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 702-703  | 1.2 | 10 |
| 109 | Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , <b>2018</b> , 90, 74-82   | 6.5 | 10 |
| 108 | Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 1-9   | 6   | 9  |
| 107 | Sex Moderates Amyloid and Apolipoprotein E Effects on Default Mode Network Connectivity at Rest. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 900   | 4.1 | 9  |
| 106 | Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 164-174  | 6   | 9  |
| 105 | A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 231-240 | 6   | 9  |
| 104 | Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 109  | 9   | 9  |
| 103 | Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 57, 387-393   | 4.3 | 8  |
| 102 | The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results. <i>BMC Neurology</i> , <b>2013</b> , 13, 3   | 3.1 | 8  |
| 101 | The utility of the new research diagnostic criteria for Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>2013</b> , 25, 175-7   | 3.4 | 8  |
| 100 | Principles of neuropsychiatry: Towards a neuropsychiatric epistemology. <i>Neurocase</i> , <b>1999</b> , 5, 181-188  | 0.8 | 8  |

|    |  |     |   |
|----|--|-----|---|
| 99 | Neuropsychiatric assessment and intervention in Alzheimer's disease. <i>International Psychogeriatrics</i> , <b>1996</b> , 8 Suppl 1, 25-30  | 3.4 | 8 |
| 98 | A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 11,   | 3.6 | 8 |
| 97 | Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer's Disease  |     | 8 |
| 96 | Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 455-61   | 1.2 | 7 |
| 95 | Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part I: Cross-Sectional and Longitudinal Assessment of Patients With Dementia. <i>American Journal of Geriatric Psychiatry</i> , <b>1994</b> , 2, 200-209  | 6.5 | 7 |
| 94 | Drug Development in Alzheimer's Disease—The Role of Default Mode Network Assessment in Phase II. <i>US Neurology</i> , <b>2017</b> , 13, 67  | 0.3 | 7 |
| 93 | The Alzheimer's disease drug development landscape. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 186  | 9   | 7 |
| 92 | Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease <b>2001</b> , 49, 355  |     | 7 |
| 91 | Alzheimer's disease drug development pipeline: 2022.. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2022</b> , 8, e12295   | 6   | 7 |
| 90 | Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 350-356 | 6   | 6 |
| 89 | The Cleveland Clinic Lou Ruvo Center for Brain Health: keeping memory alive. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 38, 103-9   | 4.3 | 6 |
| 88 | Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. <i>International Journal of Neuropsychopharmacology</i> , <b>1999</b> , 2, 59-66   | 5.8 | 6 |
| 87 | State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,   | 1.2 | 6 |
| 86 | Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 67, 303-313  | 4.3 | 6 |
| 85 | Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects. <i>Psychopharmacology Bulletin</i> , <b>2007</b> , 40, 89-98   | 0.9 | 6 |
| 84 | Alzheimer's disease summit. Translating research advances into clinical practice. Introduction. <i>CNS Spectrums</i> , <b>2008</b> , 13, 4-5   | 1.8 | 6 |
| 83 | Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 9   | 9   | 5 |
| 82 | An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 173   | 5   | 5 |



|    |  |      |   |
|----|--|------|---|
| 81 | Dextromethorphan/quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440). <i>American Journal of Geriatric Psychiatry</i> , <b>2015</b> , 23, S164-S165 | 6.5  | 5 |
| 80 | Measuring Outcomes in Alzheimer's Disease Research. <i>Disease Management and Health Outcomes</i> , <b>1999</b> , 5, 1-12  |      | 5 |
| 79 | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting <b>2001</b> , 49, 1590   |      | 5 |
| 78 | Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , <b>2021</b> , 96, 944-954   | 6.5  | 5 |
| 77 | Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2021</b> , 33, 3-13  | 2.7  | 5 |
| 76 | Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2020</b> , 49, 22-37  | 2.6  | 4 |
| 75 | Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment. <i>International Psychogeriatrics</i> , <b>2014</b> , 26, 1871-4   | 3.4  | 4 |
| 74 | Association of plasma YKL-40 with brain amyloid- $\beta$ levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , <b>2020</b> , 96, 22-32  | 5.6  | 4 |
| 73 | Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , <b>2016</b> , 6, 214-21   | 2.5  | 4 |
| 72 | Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12106   | 6    | 4 |
| 71 | Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data. <i>Neurology and Therapy</i> , <b>2021</b> , 10, 941-953                             | 4.6  | 4 |
| 70 | Why aducanumab is important. <i>Nature Medicine</i> , <b>2021</b> , 27, 1498   | 50.5 | 4 |
| 69 | Integrating symptomatic- and disease-modifying treatments. <i>CNS Spectrums</i> , <b>2008</b> , 13, 28-30  | 1.8  | 3 |
| 68 | Depression and reversible dementia in an HIV-1 seropositive individual: Implications for the dementia syndrome of depression. <i>Neurocase</i> , <b>1996</b> , 2, 455-459  | 0.8  | 3 |
| 67 | Atypical dementia syndrome in an elderly man. <i>Journal of the American Geriatrics Society</i> , <b>1987</b> , 35, 1116-26  | 3.6  | 3 |
| 66 | Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.. <i>Alzheimer's Research and Therapy</i> , <b>2022</b> , 14, 7   | 9    | 3 |
| 65 | Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 83, 1703-1715         | 4.3  | 3 |
| 64 | The costs of developing treatments for Alzheimer's disease: A retrospective exploration. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,   | 1.2  | 3 |

|    |   |      |   |
|----|---|------|---|
| 63 | Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1166-7   | 27.4 | 2 |
| 62 | Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 19, 375-88   | 4.3  | 2 |
| 61 | β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 130  | 9    | 2 |
| 60 | Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 81, 1649-1662   | 4.3  | 2 |
| 59 | Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2020</b> , 33, 124-134  | 3.8  | 2 |
| 58 | The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. <i>Multivariate Behavioral Research</i> , <b>2021</b> , 56, 70-85   | 2.3  | 2 |
| 57 | Who funds Alzheimer's disease drug development?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12185   | 6    | 2 |
| 56 | Aducanumab: Appropriate Use Recommendations Update.. <i>Journal of Prevention of Alzheimer's Disease</i> , <b>2022</b> , 9, 221-230   | 3.8  | 2 |
| 55 | Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.. <i>Alzheimer's Research and Therapy</i> , <b>2022</b> , 14, 54  | 9    | 2 |
| 54 | FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12098   | 5.2  | 1 |
| 53 | Commentary on: L-methylfolate, methylcobalamin, and N-acetylcysteine in the treatment of Alzheimer's disease-related cognitive decline. <i>CNS Spectrums</i> , <b>2010</b> , 15, 7  | 1.8  | 1 |
| 52 | Barriers to behavioral research on dementia. <i>International Psychogeriatrics</i> , <b>1996</b> , 8 Suppl 1, 21-3  | 3.4  | 1 |
| 51 | Treatment of Depression in the Patient with Parkinson's Disease <b>1998</b> , 6, 34-46  |      | 1 |
| 50 | Brain Health Living Labs. <i>American Journal of Geriatric Psychiatry</i> , <b>2021</b> , 29, 698-703   | 6.5  | 1 |
| 49 | Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 136   | 9    | 1 |
| 48 | Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12136 | 6    | 1 |
| 47 | Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography.. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2022</b> , appineuropsych21050135   | 2.7  | 1 |
| 46 | Alzheimer's Disease Drug Development: A Research and Development Ecosystem <b>2022</b> , 1-24   |      | 1 |

|    |  |      |   |
|----|--|------|---|
| 45 | Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2020</b> , 6, e12115  | 6    | o |
| 44 | The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs. <i>Journal of Prevention of Alzheimer's Disease</i> , <b>2020</b> , 7, 288-290   | 3.8  | o |
| 43 | International Psychogeriatric Association (IPA) consensus for defining psychosis in major and mild neurocognitive disorders. <i>International Psychogeriatrics</i> , <b>2021</b> , 1-5   | 3.4  | o |
| 42 | Building brain capital. <i>Neuron</i> , <b>2021</b> , 109, 1430-1432   | 13.9 | o |
| 41 | Assessing Clinical Change in Individuals Exposed to Repetitive Head Impacts: The Repetitive Head Impact Composite Index. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 605318  | 4.1  | o |
| 40 | Financing Alzheimer's Disease Drug Development <b>2022</b> , 465-479   |      | o |
| 39 | Affective Computing for Late-Life Mood and Cognitive Disorders.. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 782183   | 3.3  | o |
| 38 | Treatment of Alzheimer's disease 415-424   |      |   |
| 37 | Key developmental milestones for tau therapeutics. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044896   | 1.2  |   |
| 36 | Challenges and Opportunities to Conduct Global Alzheimer's Disease Clinical Trials <b>2014</b> , 61-75   |      |   |
| 35 | Clinical Trials in Dementia. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , <b>2007</b> , 2, 39-78   |      |   |
| 34 | Progress in Neurotherapeutics and Neuropsychopharmacology 2007. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , <b>2007</b> , 2, 1-12   |      |   |
| 33 | Geriatric Neuropsychopharmacology: Unmet Needs. <i>Psychogeriatrics</i> , <b>2001</b> , 1, 14-26   | 1.8  |   |
| 32 | Anti-dementia drugs: what difference do they make?. <i>Reviews in Clinical Gerontology</i> , <b>1998</b> , 8, 279-280  |      |   |
| 31 | Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials.. <i>Journal of Prevention of Alzheimer's Disease</i> , <b>2022</b> , 9, 241-246 | 3.8  |   |
| 30 | Pimavanserin and dementia-related psychosis.. <i>Lancet Neurology</i> , <b>2022</b> , 21, 114-115  | 24.1 |   |
| 29 | Development and assessment of a brief screening tool for psychosis in dementia.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , 13, e12254  | 5.2  |   |
| 28 | Depression and reversible dementia in an HIV-1 seropositive individual: Implications for the dementia syndrome of depression. <i>Neurocase</i> , <b>1996</b> , 2, 455-459  | 0.8  |   |

- 27 Principles of neuropsychiatry: Towards a neuropsychiatric epistemology. *Neurocase*, **1999**, 5, 181-188 o.8
- 26 Atypical Alzheimer's Disease, Mixed Dementia, and Amyloid Angiopathy **2017**, 39-47
- 25 Clinical Trials in Dementia<sup>1</sup>
- 24 Innovative Therapeutic Development Programme for the Treatment of Early Alzheimer's Disease: Lecanemab (BAN2401). *Touch Reviews in Neurology*, **2021**, 17, 70
- 23 Biobanking and Biomarkers in the Alzheimer's Disease Drug-Development Ecosystem **2022**, 123-134
- 22 ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development **2022**, 177-189
- 21 The Role of the Contract Research Organization in Alzheimer's Disease: The Vital Link in the Clinical Drug-Development Program **2022**, 309-318
- 20 Globalization of Alzheimer's Disease Clinical Trials **2022**, 275-280
- 19 The Use and Development of Clinical Measures of Alzheimer's Disease Trials **2022**, 281-291
- 18 Introduction to Venture Capital in Alzheimer's Disease Drug Development **2022**, 524-532
- 17 The Harrington Discovery Institute and Alzheimer's Disease Drug Development **2022**, 45-53
- 16 The Importance of Phase 2 in Drug Development for Alzheimer's Disease **2022**, 150-161
- 15 Artificial Intelligence in Alzheimer's Drug Discovery **2022**, 62-72
- 14 Role of Animal Models in Alzheimer's Disease Drug Development **2022**, 73-94
- 13 Institutional Review Boards and Oversight of Alzheimer's Disease Trials **2022**, 429-436
- 12 Alzheimer's Disease Clinical Trial Study Partners **2022**, 333-342
- 11 Drug Development for Alzheimer's Disease: An Historical Perspective **2022**, 25-33
- 10 Valley of Death and the Role of Venture Philanthropy in Alzheimer's Disease Drug Development **2022**, 480-485

- 9 Alzheimer's Disease Neuroimaging Initiative **2022**, 455-464
- 8 Best Practices for Clinical Trials during COVID-19 **2022**, 354-360
- 7 Alzheimer's Disease Drug Development in Pharmaceutical Companies **2022**, 162-169
- 6 Development of Fluid Biomarkers for Alzheimer's Disease **2022**, 361-374
- 5 Statistical Considerations in the Design and Analysis of Alzheimer's Disease Clinical Trials **2022**, 232-248
- 4 Development and assessment of a brief screening tool for psychosis in dementia.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 8, e057766 1.2
- 3 Pioglitazone reduces the incidence of Alzheimer's disease: From genetics to population-based validation.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e051950 1.2
- 2 Multimodal single-cell/nucleus RNA-sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e051952 1.2
- 1 Sex Modulates the Pathological Aging Effect on Caudate Functional Connectivity in Mild Cognitive Impairment.. *Frontiers in Psychiatry*, **2022**, 13, 804168 5